RJA
VIR icon

Raymond James & Associates’s Vir Biotechnology VIR Stock Holding History

Raymond James & Associates’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-74,113
Closed -$660K – 4111
2024
Q2 		$660K Buy
+74,113
New +$711K ﹤0.01% 2890
2021
Q2 		– Sell
-3,975
Closed -$204K – 4221
2021
Q1 		$204K Sell
3,975
-13,575
-77% -$732K ﹤0.01% 3600
2020
Q4 		$470K Buy
17,550
+4,150
+31% +$135K ﹤0.01% 2852
2020
Q3 		$460K Buy
13,400
+206
+2% +$8.87K ﹤0.01% 2692
2020
Q2 		$541K Buy
+13,194
New +$443K ﹤0.01% 2529

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Raymond James & Associates's VIR Position: Q3 2024 in Review

Raymond James & Associates sold out of Vir Biotechnology (VIR) in Q3 2024, closing a stake of 74,113 shares — an estimated $660K sold.

Raymond James & Associates first reported a position in VIR in Q2 2020 and held it in 5 quarters. The position peaked at $660K in Q2 2024. 197 funds tracked by Wall St. Rank hold VIR as of Q3 2024.

  • Raymond James & Associates reported no remaining Vir Biotechnology position as of Q3 2024 after selling out during the quarter.
  • Raymond James & Associates sold 74,113 Vir Biotechnology shares in Q3 2024, an estimated $660K.
  • Raymond James & Associates first reported a position in Vir Biotechnology in Q2 2020 and held it in 5 quarters.
  • Raymond James & Associates's Vir Biotechnology position peaked at $660K in Q2 2024.
  • 197 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.